Positive Results Boost Immutep Shares

  • Immutep shares rise after positive mid-stage study data for neck and head cancer treatment
  • Objective response rate of 35.5% and disease control rate of 58.1% reported
  • Efti drug combination with Merck & Co.’s Keytruda shows promising results
  • Fast track designation from FDA for quicker approval process

Immutep shares surged on Friday following the release of promising mid-stage study data for its neck and head cancer treatment. The biotechnology company reported an objective response rate of 35.5% and a disease control rate of 58.1% when using its Efti drug in combination with Merck & Co.’s Keytruda therapy as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma patients. Immutep plans to discuss the results with regulatory agencies due to the high unmet medical need. The company also received fast track designation from the FDA, allowing for a quicker approval process. On June 3, Immutep announced an agreement with Merck & Co. for a phase 3 trial.

Factuality Level: 10
Factuality Justification: The article provides accurate and objective information about the results of a clinical trial, the company’s collaboration with Merck & Co., and the FDA’s fast track designation for Efti. It does not contain any digressions, misleading information, sensationalism, redundancy, or personal perspective presented as fact.
Noise Level: 2
Noise Justification: The article provides relevant and accurate information about the positive results of a mid-stage study for Immutep’s Efti drug in combination with Keytruda for head and neck cancer treatment, as well as the fast track designation from FDA. It also mentions the agreement with Merck & Co. for a phase 3 trial. The article stays on topic and supports its claims with data.
Public Companies: Immutep (unknown), Merck & Co. (unknown)
Key People: Michael Susin (Author)

Financial Relevance: Yes
Financial Markets Impacted: Immutep and Merck & Co.
Financial Rating Justification: The article discusses the positive results of a mid-stage study on Immutep’s drug Efti in combination with Merck & Co.’s therapy Keytruda, leading to an increase in Immutep’s share price. This directly impacts the financial markets and companies involved.
Presence Of Extreme Event: No
Nature Of Extreme Event: Other
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event mentioned in the article.

Reported publicly: www.marketwatch.com